Literature DB >> 28874381

Efficacy of a New Recrystallized Enrofloxacin Hydrochloride-Dihydrate against Leptospirosis in a Hamster Model.

Alma Carrascosa1, Lilia Gutierrez1, Alejandro De la Peña2, Irma E Candanosa2, Graciela Tapia3, Hector Sumano4.   

Abstract

A trial on Syrian hamsters (Mesocricetus auratus) infected with Leptospira interrogans serovar Canicola was established to compare treatment efficacies of daily intramuscular (i.m.) injections of either 10 mg/kg of 5% enrofloxacin (Baytril [BE]; Bayer Animal Health, Mexico) or the same dose of enrofloxacin hydrochloride-dihydrate (enro-C). Hamsters were experimentally infected via the oral submucosa with 400 microorganisms/animal, in a sequential time schedule aligned to the initial treatment day, and were treated in groups as follows: a group treated with 5% enrofloxacin daily for 7 days after 24 h of infection (group BE24); a group treated as described for group BE24 but with enro-C (enro-C24); a group also treated with 5% enrofloxacin but starting at 72 h after infection (BE74); a group treated as described for group BE74 but with injection of enro-C (enro-C74). An untreated-uninfected control group (group CG-) and an infected-untreated control group (group CG+) were assembled (n = 18 in all groups). Weights and temperatures of the hamsters were monitored daily for 28 days. After hamsters were euthanatized or following death, necropsy, histopathology, macroscopic agglutination tests (MAT), bacterial culture, and PCR were performed. The mortality rates were 38.8% in group BE24 and 100% in group BE74 No mortality was observed in group enro-C24, and 11.1% mortality was recorded in group enro-C74 The mortality rates in groups CG+ and CG- were 100% and zero, respectively. Combined necropsy and histopathologic findings revealed signs of septicemia and organ damage in groups BE24, BE72, and CG+ Groups enro-C24 and CG- showed no lesions. Moderated lesions were registered in 3 hamsters in group enro-C72 MAT results were positive in 83.3% of BE24 hamsters (83.3%) and 100% of BE72 and CG+ hamsters; MAT results were positive in 16.7% in group Enro-C24 and 38.9% in group enro-C72 Only 4/18 were PCR positive in group enro-C72 and only 1 in group enro-C24 (P < 0.05). It can be concluded that enro-C may be a viable option to treat leptospirosis in hamsters and that this may be the case in other species.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Leptospira interrogans; enrofloxacin; golden hamster (Mesocricetus auratus)

Mesh:

Substances:

Year:  2017        PMID: 28874381      PMCID: PMC5655069          DOI: 10.1128/AAC.01285-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Overview of the epidemiology, microbiology, and pathogenesis of Leptospira spp. in humans.

Authors:  R Plank; D Dean
Journal:  Microbes Infect       Date:  2000-08       Impact factor: 2.700

Review 2.  The pharmacokinetic-pharmacodynamic approach to a rational dosage regimen for antibiotics.

Authors:  P L Toutain; J R E del Castillo; A Bousquet-Mélou
Journal:  Res Vet Sci       Date:  2002-10       Impact factor: 2.534

3.  In vitro sensitivity and resistance of 46 Leptospira strains isolated from rats in the Philippines to 14 antimicrobial agents.

Authors:  Antara Chakraborty; Satoshi Miyahara; Sharon Y A M Villanueva; Nina G Gloriani; Shin-Ichi Yoshida
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

Review 4.  Emergence, control and re-emerging leptospirosis: dynamics of infection in the changing world.

Authors:  R A Hartskeerl; M Collares-Pereira; W A Ellis
Journal:  Clin Microbiol Infect       Date:  2011-04       Impact factor: 8.067

Review 5.  Leptospirosis in humans.

Authors:  David A Haake; Paul N Levett
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 6.  Leptospira and leptospirosis.

Authors:  Ben Adler; Alejandro de la Peña Moctezuma
Journal:  Vet Microbiol       Date:  2009-03-13       Impact factor: 3.293

7.  Physicochemical characterization and pharmacokinetics in broiler chickens of a new recrystallized enrofloxacin hydrochloride dihydrate.

Authors:  L Gutierrez; J E Miranda-Calderon; P Garcia-Gutierrez; H Sumano
Journal:  J Vet Pharmacol Ther       Date:  2014-09-16       Impact factor: 1.786

8.  2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention.

Authors:  J E Sykes; K Hartmann; K F Lunn; G E Moore; R A Stoddard; R E Goldstein
Journal:  J Vet Intern Med       Date:  2010-12-13       Impact factor: 3.333

9.  Kinetics of Leptospira interrogans infection in hamsters after intradermal and subcutaneous challenge.

Authors:  Mariana L Coutinho; James Matsunaga; Long-Chieh Wang; Alejandro de la Peña Moctezuma; Michael S Lewis; Jane T Babbitt; Jose Antonio G Aleixo; David A Haake
Journal:  PLoS Negl Trop Dis       Date:  2014-11-20

10.  Enrofloxacin hydro-chloride dihydrate.

Authors:  Jorge E Miranda-Calderón; Lilia Gutiérrez; Marcos Flores-Alamo; Ponciano García-Gutiérrez; Héctor Sumano
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-03-26
View more
  4 in total

1.  Outpatient Clinical Trial in Dogs With Leptospirosis Treated With Enrofloxacin Hydrochloride-Dihydrate (ENRO-C).

Authors:  Lilia Gutierrez; Jesús Mendoza; Ana Bertha Rangel; Graciela Tapia; Maria Josefa Bernad; Hector Sumano
Journal:  Front Vet Sci       Date:  2019-10-15

2.  Isolation of Leptospira serovar Pomona from a crested porcupine (Hystrix cristata, L., 1758).

Authors:  Giovanni Cilia; Fabrizio Bertelloni; Francesca Coppola; Barbara Turchi; Claudia Biliotti; Alessandro Poli; Francesca Parisi; Antonio Felicioli; Domenico Cerri; Filippo Fratini
Journal:  Vet Med Sci       Date:  2020-06-17

3.  Pharmacokinetics of enrofloxacin HCl-2H2O (Enro-C) in dogs and pharmacokinetic/pharmacodynamic Monte Carlo simulations against Leptospira spp.

Authors:  Hector Sumano; Luis Ocampo; Graciela Tapia; Corazon de Jesus Mendoza; Lilia Gutierrez
Journal:  J Vet Sci       Date:  2018-09-30       Impact factor: 1.672

4.  Formation of inclusion complex of enrofloxacin with 2-hydroxypropyl-β-cyclodextrin.

Authors:  Yili Ding; Yuchang Pang; Chamakura V N S Vara Prasad; Bingyun Wang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.